Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis
Recruiting · NCT07301892 · Observational (researchers observe without assigning treatment) · Lead sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Generative AI (GenAI) based on large language models (LLMs) is expected to improve the diagnosis and treatment of autoimmune diseases. We are studying how GenAI may affect the diagnosis of various complications of rheumatoid arthritis (RA). In a retrospective study using RA patients' EHR records, we will quantify physician adoption of GenAI predictions for RA complications and co-existing diseases. In a prospective observational study, we will assess the feasibility of using GenAI predictions as additional clinical information to help physicians make more complete diagnoses of RA complications and co-existing diseases, including complex, uncommon, or rare conditions.
Who can take part
Inclusion criteria
- Patients with an initial diagnosis of rheumatoid arthritis (RA).
- All real-world RA inpatients admitted to our department.
- Admission occurring within the real-world data study period.
Exclusion criteria
- Patients subsequently confirmed not to have RA during the study.
Where it is running
3 locations listed.
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences - Beijing, Beijing Municipality, China
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences - Beijing, Beijing Municipality, China
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences - Beijing, Beijing Municipality, China